The development of DNA vaccines against SARS-CoV-2

Background The COVID-19 pandemic exerted significant impacts on public health and global economy. Research efforts to develop vaccines at warp speed against SARS-CoV-2 led to novel mRNA, viral vectored, and inactivated vaccines being administered. The current COVID-19 vaccines incorporate the full...

Full description

Saved in:
Bibliographic Details
Main Authors: Kanwal, Khalid *, Poh, Chit Laa *
Format: Article
Published: Elsevier 2023
Subjects:
Online Access:http://eprints.sunway.edu.my/2825/
https://doi.org/10.1016/j.advms.2023.05.003
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Sunway University
id my.sunway.eprints.2825
record_format eprints
spelling my.sunway.eprints.28252024-07-16T01:53:21Z http://eprints.sunway.edu.my/2825/ The development of DNA vaccines against SARS-CoV-2 Kanwal, Khalid * Poh, Chit Laa * QR Microbiology RA Public aspects of medicine RM Therapeutics. Pharmacology Background The COVID-19 pandemic exerted significant impacts on public health and global economy. Research efforts to develop vaccines at warp speed against SARS-CoV-2 led to novel mRNA, viral vectored, and inactivated vaccines being administered. The current COVID-19 vaccines incorporate the full S protein of the SARS-CoV-2 Wuhan strain but rapidly emerging variants of concern (VOCs) have led to significant reductions in protective efficacies. There is an urgent need to develop next-generation vaccines which could effectively prevent COVID-19. Methods PubMed and Google Scholar were systematically reviewed for peer-reviewed papers up to January 2023. Results A promising solution to the problem of emerging variants is a DNA vaccine platform since it can be easily modified. Besides expressing whole protein antigens, DNA vaccines can also be constructed to include specific nucleotide genes encoding highly conserved and immunogenic epitopes from the S protein as well as from other structural/non-structural proteins to develop effective vaccines against VOCs. DNA vaccines are associated with low transfection efficiencies which could be enhanced by chemical, genetic, and molecular adjuvants as well as delivery systems. Conclusions The DNA vaccine platform offers a promising solution to the design of effective vaccines. The challenge of limited immunogenicity in humans might be solved through the use of genetic modifications such as the addition of nuclear localization signal (NLS) peptide gene, strong promoters, MARs, introns, TLR agonists, CD40L, and the development of appropriate delivery systems utilizing nanoparticles to increase uptake by APCs in enhancing the induction of potent immune responses. Elsevier 2023 Article PeerReviewed Kanwal, Khalid * and Poh, Chit Laa * (2023) The development of DNA vaccines against SARS-CoV-2. Advances in Medical Sciences, 68 (2). pp. 213-226. ISSN 1898-4002 https://doi.org/10.1016/j.advms.2023.05.003 10.1016/j.advms.2023.05.003
institution Sunway University
building Sunway Campus Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Sunway University
content_source Sunway Institutional Repository
url_provider http://eprints.sunway.edu.my/
topic QR Microbiology
RA Public aspects of medicine
RM Therapeutics. Pharmacology
spellingShingle QR Microbiology
RA Public aspects of medicine
RM Therapeutics. Pharmacology
Kanwal, Khalid *
Poh, Chit Laa *
The development of DNA vaccines against SARS-CoV-2
description Background The COVID-19 pandemic exerted significant impacts on public health and global economy. Research efforts to develop vaccines at warp speed against SARS-CoV-2 led to novel mRNA, viral vectored, and inactivated vaccines being administered. The current COVID-19 vaccines incorporate the full S protein of the SARS-CoV-2 Wuhan strain but rapidly emerging variants of concern (VOCs) have led to significant reductions in protective efficacies. There is an urgent need to develop next-generation vaccines which could effectively prevent COVID-19. Methods PubMed and Google Scholar were systematically reviewed for peer-reviewed papers up to January 2023. Results A promising solution to the problem of emerging variants is a DNA vaccine platform since it can be easily modified. Besides expressing whole protein antigens, DNA vaccines can also be constructed to include specific nucleotide genes encoding highly conserved and immunogenic epitopes from the S protein as well as from other structural/non-structural proteins to develop effective vaccines against VOCs. DNA vaccines are associated with low transfection efficiencies which could be enhanced by chemical, genetic, and molecular adjuvants as well as delivery systems. Conclusions The DNA vaccine platform offers a promising solution to the design of effective vaccines. The challenge of limited immunogenicity in humans might be solved through the use of genetic modifications such as the addition of nuclear localization signal (NLS) peptide gene, strong promoters, MARs, introns, TLR agonists, CD40L, and the development of appropriate delivery systems utilizing nanoparticles to increase uptake by APCs in enhancing the induction of potent immune responses.
format Article
author Kanwal, Khalid *
Poh, Chit Laa *
author_facet Kanwal, Khalid *
Poh, Chit Laa *
author_sort Kanwal, Khalid *
title The development of DNA vaccines against SARS-CoV-2
title_short The development of DNA vaccines against SARS-CoV-2
title_full The development of DNA vaccines against SARS-CoV-2
title_fullStr The development of DNA vaccines against SARS-CoV-2
title_full_unstemmed The development of DNA vaccines against SARS-CoV-2
title_sort development of dna vaccines against sars-cov-2
publisher Elsevier
publishDate 2023
url http://eprints.sunway.edu.my/2825/
https://doi.org/10.1016/j.advms.2023.05.003
_version_ 1805893818474561536